Harvard Bioscience CFO buys 5,000 shares
Harvard Bioscience Chief Financial Officer Mark T. Frost bought 5,000 shares of common stock in an open-market purchase at $5.00 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Harvard Bioscience Chief Financial Officer Mark T. Frost bought 5,000 shares of common stock in an open-market purchase at $5.00 per share. Following this transaction, he directly owns a total of 17,500 shares, including 10,000 restricted stock units scheduled to vest on May 12, 2026.
Insider Trade Summary
Net Buyer: 5,000 shares
Net Buy
1 txn
Insider
Frost Mark T
Role
Chief Financial Officer
Bought
5,000 shs ($25K)
Increase in Position
40.0%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 5,000 | $5.00 | $25K |
Holdings After Transaction:
Common Stock — 17,500 shares (Direct)
Holdings Before and After:
Common Stock, 12,500 to 17,500 shares (Direct)
Other Insiders: 3 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (2)
- F1. Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) 10,000 restricted stock units that will vest on May 12, 2026, and (c) 2,500 shares of common stock beneficially owned by the Reporting Person.
- F2. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 100,000 restricted stock units and the 2,500 shares of common stock referenced in Footnote 1(c) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Key Figures
Shares purchased: 5,000 shares
Purchase price: $5.00 per share
Total shares after transaction: 17,500 shares
+2 more
5 metrics
Shares purchased
5,000 shares
Open-market purchase on March 16, 2026
Purchase price
$5.00 per share
Common Stock transaction code P
Total shares after transaction
17,500 shares
Direct holdings including RSUs and common stock
Restricted stock units
10,000 units
RSUs scheduled to vest on May 12, 2026
Reverse stock split ratio
10-for-1
Common stock reverse split on March 13, 2026
Key Terms
restricted stock units, reverse stock split, beneficially owned, open-market purchase
4 terms
restricted stock units financial
"10,000 restricted stock units that will vest on May 12, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
reverse stock split financial
"the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
beneficially owned financial
"2,500 shares of common stock beneficially owned by the Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Harvard Bioscience (HBIO) report for its CFO?
Harvard Bioscience CFO Mark T. Frost bought 5,000 common shares. He purchased the shares in an open-market transaction at $5.00 per share, increasing his direct holdings to a total of 17,500 shares, including restricted stock units.
What type of transaction did the Harvard Bioscience (HBIO) CFO execute?
The transaction was an open-market purchase of common stock. The Form 4 classifies the March 16, 2026 activity under code “P,” meaning a purchase in an open market or private transaction, rather than a sale or derivative exercise.
Did a reverse stock split affect the Harvard Bioscience (HBIO) CFO’s reported holdings?
Yes, a 10-for-1 reverse stock split adjusted prior figures. Footnotes explain that restricted stock units and previously reported common shares were divided by 10 to reflect a reverse stock split effective March 13, 2026.
What future vesting is disclosed for the Harvard Bioscience (HBIO) CFO’s equity awards?
10,000 restricted stock units are scheduled to vest on May 12, 2026. These units are included in the 17,500 total shares reported as beneficially owned following the March 16, 2026 open-market purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
